Find It™ screens for 120 genetic mutations in cancer patients
CORE Diagnostics gets exclusive distributorship of Find It™ in India
Will be marketed in India by the name of geneCORE Hotspot.
New Delhi, India and Vancouver, Canada – August 9st 2017: Indian diagnostics start up CORE Diagnostics has tied up with leading Canadian company Contextual Genomics to introduce a potentially revolutionary genomic test in India — Find It™ – the test evaluates the mutation status of tumor DNA at more than 120 well-characterized positions, identifying the somatic mutations that have the greatest potential to impact treatment decisions, making it possible for doctors to customize therapies with greater precision.
CORE Diagnostics, has the exclusive distributorship of the test in India, and will be introducing it by the name of geneCORE Hotspot. The partnership marks a major milestone in CORE Diagnostics quest to improve cancer treatment in India.
Contextual Genomics is a leading name in the field of genomics-based cancer tests, and has played a pioneering role in Personalized Medicine. Contextual Genomics assays are designed to find mutational information that allows oncologists and patients to make appropriate treatment decisions, based on specific abnormalities in the tumors.
“We are elated to announce this partnership that allows us to bring to India one of the most significant diagnostic developments in the field of oncology and personalized medicine. With improving understanding of cancers, there is uniform agreement in the field of medicine today about the need for making genomic testing a critical component of cancer treatment. geneCORE Hotspot is a major diagnostic advancement that will allow doctors to treat each patient in a unique way by identifying the mutations driving his/her disease. This test has the potential to revolutionize cancer care,” says Zoya Brar, MD & Founder, CORE Diagnostics.
geneCORE Hotspot detects common, clinically actionable genomic alterations in solid tumors and reports them back to the user, in four weeks from histology to a report.
“Each cancer is different and needs individualized treatment plan to allow patients the best chance of recovery. We strongly believe that genomic testing will become standard practice in cancer care to give patients access to the most effective treatment option based on their tumour profile. Find It™ genomics test provides in depth information on specific abnormalities in tumors, thereby giving physicians an insight into whether a patient will respond and benefit from a specific treatment. We are delighted to partner with CORE Diagnostics to help us make this test available in India,” said Chris Wagner, President & CEO, Contextual Genomics.
GeneCORE Hotspot reports will feature a detailed clinical interpretation, with recommendations based on the mutation profile of the tumor. In geneCORE Hotspot Panel separate reports will be generated for the physician and the patient. This seamless, full-service approach will enable physicians to make more informed treatment decisions. Based on the presence of a specific mutation in a cancer, healthcare providers can select the most appropriate treatment for the patient. It will offer patients the most useful cancer management plan available and suitable to them, thereby improving chances of long term survival.
Cancer is driven by multiple aberrations that are unique to each patient. Knowing what these aberrations or mutations are, empowers oncologists to select the best treatment plan for the patient. The test can study over 120 carefully selected clinically actionable cancer hotspots in one panel applicable to most solid tumors. It is a multiplex, genomic assay designed for next- generation sequencing in a CLIA certified environment. It evaluates the mutation status of tumor DNA at over 120 well-characterized positions within cancer genes.
About CORE Diagnostics:
CORE Diagnostics is a clinical laboratory focused on next generation diagnostics for disease stratification and therapy selection. The company focuses on bringing the most advanced testing techniques and expertise to India and is the destination for all of India’s high-end diagnostic needs. CORE Diagnostics is truly one of a kind, because of: A rich menu of high-end tests; second opinion on every test from a global panel of pathologists; and very short turnaround time. The company’s initial test offerings have been in the areas of cardiology, oncology, reproductive disorders, endocrinology, and infectious diseases. For more information, please visit www.corediagnostics.in.
About Contextual Genomics:
Contextual Genomics (www.contextualgenomics.com) has developed cost-effective and clinically actionable molecular tests that guide diagnosis and treatment of cancer. These customized tests are designed to be offered by partner laboratories around the world with Contextual conducting bioinformatics services via a SaaS model. The collection of data via this robust network of partners and the use of machine-learning tools will allow Contextual Genomics to improve patient care through improved clinical trial enrolment and new treatment algorithms.
Contextual is managed by global leaders in cancer research and bioinformatics, who have unparalleled expertise in cancer genomics and the clonal evolution of cancer.
Contextual Genomics Media
President and CEOContextual Genomics
Contact CORE Diagnostics
Dr. Akanksha Mago
General Manager – Corporate Communications
This release contains forward-looking statements that are not based on historical facts. These forward-looking statements involve risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from those expressed or implied by such forward-looking statements. Readers are cautioned not to place undue reliance on such forward-looking statements.